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Design of clinical trials to evaluate drugs
has been moving to increasing levels of
complexity. Multicenter, multinational tri-
als have been required to determine the
clinical indications for a new drug and to
receive licensure across the global market.
Problems in trial design, discovered after
a large, expensive trial has been completed,
can delay drug development and waste the
limited resources of both the investigators
and the industry. Compromises in trial de-
sign or size, made to expedite the devel-
opment process, produce information that
is of limited value and easily misinter-
preted, to the detriment of patient care.
Complex studies provide more informa-
tion but require more clinician expertise
to understand. Investigators conducting
clinical trials have the obligation not only
to improve the design of clinical trials but
also to publish results in a way that makes
both the findings and the limitations of
the study apparent to the clinician. Clin-
ical investigators, the pharmaceutical in-
dustry, and regulatory agencies have a
shared responsibility for improving the
process by which drugs are evaluated and
explained to physicians involved in patient
care.
Discussions at the Forum largely cen-
tered on design of drug trials but also in-
cluded trials of a diagnostic test. The group
focused on the analysis of certain recent
pivotal trials with the intent to discern
what these trials have to teach us about
design of future trials. A session chairper-
son introduced each topic. A nominated
speaker made a presentation, and further
analysis was contributed by one or more
discussants and by general discussion.
The Forum proceedings are presented
in three parts. The first part concerns is-
sues in clinical trials of empirical antifun-
gal therapy to treat febrile neutropenic pa-
tients. The second part deals with issues
in design of drug trials for invasive as-
pergillosis. The third part has three com-
ponents: issues in the evaluation of diag-
nostic tests, use of historical controls, and
merits of the current multicenter collab-
orative trial groups.
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